inMIND study in R/R follicular lymphoma

Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.

inMIND is a global, phase 3, double-blind RCT. It evaluated the efficacy and safety of adding tafasitamab to lenalidomide and rituximab (Len+R) in patients with relapsed/refractory follicular lymphoma (R/R FL) or marginal zone lymphoma. The trial was powered to assess PFS in patients with FL as the primary endpoint. A total of 548 patients were randomised equally into the experimental and control arms.

Results demonstrated a significant improvement in the experimental arm with tafasitamab. With a median follow-up of 14.1 months, patients receiving tafasitamab with Len+R showed a median investigator-assessed PFS of 22.4 months versus 13.9 months in the placebo group (HR 0.43; 95% CI, 0.32–0.58; P<0.0001). Independent review committee analysis confirmed these findings, with the median PFS not reached in the tafasitamab arm versus 16.0 months in the placebo arm (HR 0.41; 95% CI, 0.29–0.56; P<0.0001). The PFS benefit with tafasitamab was consistent across all prespecified subgroups, including patients with POD24, those refractory to prior anti-CD20 monoclonal antibodies, and those who had received multiple prior lines of therapy. Although OS data remain immature, there is a trend favoring tafasitamab.

The safety profile was manageable and aligned with expected toxicities, suggesting feasibility in clinical practice.

Based on these results, tafasitamab, in combination with Len+R, offers significant potential as a new standard treatment option for patients with R/R FL.